What is the appropriate starting dose and dosing frequency of cinacalcet for a patient with end‑stage renal disease?

Cinacalcet Dosing for ESRD Patients

For ESRD patients on dialysis with secondary hyperparathyroidism, start cinacalcet at 30 mg once daily, taken with food, and titrate every 2-4 weeks through sequential doses of 30,60,90,120, and 180 mg once daily to target iPTH levels of 150-300 pg/mL. 1

Starting Dose and Administration

The FDA-approved starting dose is 30 mg once daily 1. Key administration points:

• Take with food or shortly after a meal to optimize absorption
• Swallow tablets whole—do not crush, chew, or divide
• Dosing frequency is once daily for ESRD patients on dialysis

Dose Titration Schedule

Titrate no more frequently than every 2-4 weeks through the following sequential doses 1:

• 30 mg once daily (starting dose)
• 60 mg once daily
• 90 mg once daily
• 120 mg once daily
• 180 mg once daily (maximum dose)

The target is to achieve iPTH levels of 150-300 pg/mL 1.

Monitoring Requirements

Initial Monitoring

• Serum calcium and phosphorus: within 1 week of initiation or dose adjustment
• iPTH: 1-4 weeks after initiation or dose adjustment (measure no earlier than 12 hours after dosing) 1

Maintenance Monitoring

Once the maintenance dose is established, measure serum calcium approximately monthly 1.

Critical Safety Considerations

Hypocalcemia Management

Cinacalcet significantly increases hypocalcemia risk (RR 7.38) 2. Do not initiate if serum calcium is below the lower limit of normal 1.

If calcium falls below 8.4 mg/dL but remains above 7.5 mg/dL:

• Increase calcium-containing phosphate binders
• Increase vitamin D sterols
• Continue cinacalcet 1

If calcium falls below 7.5 mg/dL or symptomatic hypocalcemia persists:

• Withhold cinacalcet until calcium reaches ≥8 mg/dL and symptoms resolve
• Restart at the next lowest dose 1

Clinical Context and Evidence Quality

The 2018 KDIGO guidelines 3 suggest cinacalcet as one option (alongside calcitriol or vitamin D analogues) for PTH-lowering therapy in CKD G5D patients, but notably do not prioritize it as first-line. This reflects the EVOLVE trial findings showing cinacalcet had no significant effect on all-cause mortality (RR 0.97) or cardiovascular mortality 2.

The primary benefit of cinacalcet is preventing surgical parathyroidectomy (RR 0.49), but this prevents only about 3 parathyroidectomies per 1,000 patients treated for one year, while causing hypocalcemia in approximately 60 patients and nausea in 150 patients 2.

Common Pitfalls to Avoid

1. Do not use cinacalcet in CKD patients not on dialysis—increased hypocalcemia risk 1
2. Do not titrate more frequently than every 2-4 weeks—allow time for steady-state effects 1
3. Do not measure iPTH less than 12 hours after dosing—results will be inaccurate 1
4. Monitor calcium closely during titration—hypocalcemia is common and can be severe 1

Alternative Dosing Considerations

While the FDA label specifies daily dosing, research suggests thrice-weekly in-center administration may be equally effective with similar biochemical control 4, and a twice-weekly regimen has shown efficacy in some studies 5. However, the FDA-approved and guideline-supported regimen remains once-daily dosing 1.